||Why IBD Patients Should Know About Biosimilars
Date: Wednesday, June 01, 2016
Time: 08:00 PM EDT | 7:00 PM CST | 6:00 PM MST | 5:00 PM PST
Duration: 60 mins
While not yet available in the U.S., the Food and Drug Administration recently announced its approval of a biosimilar for the treatment of Crohn’s disease and ulcerative colitis. Join us to learn more about biosimilars and hear from our experts as they answer your questions!
David Rubin, MD
University of Chicago Medicine
Noa Cleveland, MD
University of Illinois College of Medicine
This program is supported by a sponsorship from AbbVie, Inc. and an educational grant from Amgen.
Additional support of this program through CCFA’s annual giving programs and donors.